Wednesday, December 20, 2023 2:26:46 PM
No, it is an NWBO factory, which is depreciated. Advent has a lease for a small port for offices and to provide additional services to the third parties that NWBO is obligated to provide because of the regional financing.
Advent's sublease is on the entire GMP approved portion of the facility and the phase B expansion (not yet approved). This is all well documented in the SEC submissions.
That nonsense about Advent being required to provide CDMO services in order for NWBO to get that $5M loan is complete BS. Just message board hype Doc Logic posted so often even he believed it.
Anyway, details on the Advent sublease.
Hotel Suite 1 (including C lab extension) 2,238 ft2
Hotel suite 2 2,012 ft2
Labs (PD and QC). 830 ft2
Corridors 1,420 ft2
Computer room 75 ft2
---------------------------------------------------------------
Sub-Total 6,575 ft2
Unfinished and/or un-equipped interior space:
Hotel Suite 3 2,012 ft2
Hotel Suite 4 2,012 ft2
Nitrogen cryostorage area 2,560 ft2
Plant room + electrical cupboard 1,300 ft2
----------------------------------------------------------------
Sub-Total: 7,884 ft2
Total Interior Space: 14,459 ft2
Compare that to approved GMP space from the NWBO MHRA facility approval PR
To date, the Company has developed Phase 1A of the facility, comprising approximately 4,400 square feet of the overall 88,345 square feet.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
